Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PARG | Q86W56 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27126075 | 0.85 | HSP90AA1 (0.32) | KITPARP1PARP2ACHEMKNK2 | |
| SCHEMBL4097102 | 0.76 | ACHE (0.45) | L3MBTL1ACHEHTTBRD4 | |
| SCHEMBL7832849 | 0.70 | L3MBTL1 (0.36) | L3MBTL1ACHEMAPT | |
| SCHEMBL27137997 | 0.70 | HSP90AA1 (0.34) | PARP1PARP2P2RX3ACHEBRD4 | |
| SCHEMBL27124750 | 0.68 | PDE1B (0.32) | L3MBTL1HTTBRD4 | |
| SCHEMBL16652558 | 0.68 | CNR2 (0.42) | P2RX3L3MBTL1LMNAMAPT | |
| SCHEMBL20577813 | 0.66 | L3MBTL1 (0.37) | L3MBTL1LMNAMAPTHTTBRD4 | |
| SCHEMBL27120776 | 0.65 | MAP4K4 (0.52) | KIT | |
| SCHEMBL27125769 | 0.65 | HSD17B13 (0.35) | — | |
| SCHEMBL19235739 | 0.64 | L3MBTL1 (0.38) | L3MBTL1ACHEMAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | KIT 3180/4885PARP1 1067/4885PARP2 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.